Core Viewpoint - Kanglong Chemical has established itself as a leading CXO enterprise in China, providing comprehensive drug development services and is well-positioned to benefit from the growing global demand for pharmaceutical R&D outsourcing. The company is rated "Buy" with a target price of 38.08 RMB [1][3]. Group 1: Business Model and Competitive Advantage - Kanglong Chemical is one of the top two companies in China's drug discovery and preclinical CRO services, having strategically expanded into small molecule CDMO, clinical development, and large molecule and cell and gene therapy (CGT) fields, creating a one-stop CXO platform that reduces operational risks, time delays, and cost losses for clients [1]. - The one-stop CXO platform is expected to maintain a significant competitive advantage in the global market as biopharmaceutical companies increasingly prioritize R&D efficiency, speed, and reliability [1]. Group 2: Business Segment Performance - Laboratory services are the foundation of the company's long-term growth, with new orders expected to grow over 15% year-on-year in 2024, continuing a similar growth trend in the first three quarters of 2025 [2]. - The small molecule CDMO segment is highly synergistic with laboratory services, with new orders projected to grow over 35% year-on-year in 2024 and approximately 20% in the first three quarters of 2025, making it the fastest-growing business segment [2]. - Clinical research services have been integrating global clinical teams since 2021, with significant room for improvement in operational efficiency as current revenue per employee and gross margin are below industry levels [2]. - The large molecule and CGT segments are expected to provide business diversification and high-value growth in the medium to long term, driven by the rising demand for complex molecular therapies [2]. Group 3: Industry Trends and Financial Outlook - Kanglong Chemical's business performance is closely tied to macro trends in the global life sciences industry, with a notable recovery in global innovative drug R&D demand observed in the second half of 2025, including a 22.5% year-on-year increase in global innovative drug financing and a staggering 215.4% increase in China [3]. - The top 10 global pharmaceutical companies reported a 5.3% year-on-year increase in R&D spending in the first half of 2025, indicating a return to positive growth and stabilizing R&D expenditures among leading biotech companies, which strengthens the demand foundation for the CXO industry [3]. - Revenue projections for Kanglong Chemical are expected to grow by 14.2%, 14.8%, and 16.3% year-on-year for 2025, 2026, and 2027 respectively, with non-IFRS net profit growth of 12.3%, 17.8%, and 18.7% [3].

Investment Rating - The report initiates coverage on 康龙化成 with a "Buy" rating and a target price of 38.08 RMB, indicating a potential upside of 21.7% from the current price of 31.30 RMB [1][3]. Core Insights - 康龙化成 is recognized as a leading integrated CXO company in China, established in 2004, providing comprehensive services throughout the drug development lifecycle. The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing [1][7]. - The report highlights the company's strategic expansion into various sectors, including small molecule CDMO, clinical development, and large molecule & cell and gene therapy (CGT), which positions 康龙化成 as a competitive player in the global market [7]. - The company is projected to achieve revenue growth rates of 14.2%, 14.8%, and 16.3% for FY25E, FY26E, and FY27E, respectively, with adjusted net profit growth rates of 12.3%, 17.8%, and 18.7% for the same periods [7][11]. Financial Summary - For FY23A, 康龙化成 reported sales revenue of 11,538 million RMB, with a year-on-year growth of 12.4%. The adjusted net profit for the same period was 1,903 million RMB, reflecting a growth of 3.8% [2][11]. - The company’s sales revenue is expected to reach 14,022 million RMB in FY25E, with a projected growth of 14.2% year-on-year [2][11]. - The adjusted net profit is forecasted to be 1,804 million RMB in FY25E, with a year-on-year increase of 12.3% [2][11]. Shareholder Structure - The shareholder structure indicates that 19.3% of the shares are held by Hong Kong investors, while the actual controller holds 17.7% [4]. Stock Performance - The stock has shown a 1-month absolute return of 8.6% and a 6-month return of 15.1%, indicating positive market sentiment [5].